On August 19, 2022 I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, reported that it will report business and corporate updates and financial results for the six months ended June 30, 2022, before the market opens on Tuesday, August 30, 2022 (Press release, I-Mab Biopharma, AUG 19, 2022, View Source [SID1234618516]). The Company’s management will host conference calls with investors to provide updates on recent pipeline development, upcoming milestones, and potential implementation of a comprehensive share purchase program by the Company and current shareholders.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

I-Mab Conference Call Information:

Investors and analysts are invited to join the conference call at 7:00 a.m. Eastern Time for Mandarin session or 8:15 a.m. Eastern Time for English session on August 30, 2022 via Zoom